← All trials
NCT03326102
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 25, 2018
- Primary completion
- May 31, 2019
- Completion date
- Sep 30, 2019
- First posted
- —
- Last posted
- —
- Enrollment
- 72
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Daehwa Pharmaceutical Co., Ltd.Lead sponsor
- University of PittsburghOverall official - principal investigator
- University of California, San FranciscoOverall official - principal investigator
- Anne Arundel Health System Research InstituteOverall official - principal investigator
- Boca Raton Regional HospitalOverall official - principal investigator
- Harvard UniversityOverall official - principal investigator
- Saint Luke's Health SystemOverall official - principal investigator
- University of KansasOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.